Cite
Chen S, Yu SJ, Li Y, et al. Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Sci Rep. 2018;8(1):13953doi: 10.1038/s41598-018-31455-w.
Chen, S., Yu, S. J., Li, Y., Lecca, D., Glotfelty, E., Kim, H. K., Choi, H. I., Hoffer, B. J., Greig, N. H., Kim, D. S., & Wang, Y. (2018). Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Scientific reports, 8(1), 13953. https://doi.org/10.1038/s41598-018-31455-w
Chen, Shuchun, et al. "Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease." Scientific reports vol. 8,1 (2018): 13953. doi: https://doi.org/10.1038/s41598-018-31455-w
Chen S, Yu SJ, Li Y, Lecca D, Glotfelty E, Kim HK, Choi HI, Hoffer BJ, Greig NH, Kim DS, Wang Y. Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Sci Rep. 2018 Sep 12;8(1):13953. doi: 10.1038/s41598-018-31455-w. PMID: 30209317; PMCID: PMC6135809.
Copy
Download .nbib